“The EUGMP approval and the Genome Valley R&D launch mark significant steps in our journey. These milestones reinforce our global quality alignment and commitment to innovation. With enhanced capabilities, we can accelerate complex molecule development, strengthen regulated market access, and deliver value as a trusted partner worldwide.”
Growth Strategy
Targeting 30% CAGR over the next five years.
Growth to be driven by:
- Expanding product portfolio.
- Strong demand from regulated markets.
- Custom manufacturing collaborations with global healthcare partners.
New R&D centre designed to:
- Support in-house product development.
- Position Aparna as a preferred CDMO partner.
- Accelerate innovation-led solutions for global clients.
Strategic Outlook
With manufacturing scale, global certifications, and new R&D capabilities, Aparna is positioned to:
Strengthen its presence in regulated markets.
Drive innovation in APIs and complex intermediates.
Deliver safe, effective, and affordable healthcare solutions worldwide.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!